Home  >  Press Releases  >  Corporate


Press release year list 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010
January 13, 2022
Solensia™ is the first and only injectable monoclonal antibody (mAb) treatment for feline OA pain approved in the United States Monthly administration of Solensia controls OA pain by targeting Nerve Growth Factor (NGF), a key driver in OA pain Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Food and Drug Administration (FDA) has approved Solensia ™ to control the pain of osteoarthritis (OA) in cats, helping improve their mobility, comfort and overall well-being. 1 As a once-monthly injection administered in the veterinary clinic, Solensia keeps OA pain from disrupting the unique bond cats share with their humans. Feline OA, a highly prevalent condition with nearly 40% of all cats showing signs of OA pain 2 , occurs when the protective tissue in the joints (cartilage) is worn down, causing bones to rub together. This makes moving harder and causes severe pain. Without treatment, OA pain can worsen over time and seriously affect a cat’s long-term health and well-being. 3 “Feline OA ...
January 6, 2022
Commits to carbon neutrality in company operations by 2030 Accelerates commitment to 100% renewable energy Zoetis Inc. (NYSE:ZTS), the world’s leading animal health company, has refreshed its Driven to Care sustainability aspirations for mitigating the company’s climate impact and environmental effects on the planet. Focusing first on its own operations, Zoetis is striving to achieve carbon neutrality by 2030. This includes accelerating the company’s commitment to Renewable Energy 100 (RE100) to use 100% renewable energy in its operations. The company’s updated commitments are underscored by investments in technology and a strong governance structure. “Our vision is to be the most sustainable animal health company in the world, and we are proud to be the first stand-alone animal health company to commit to carbon neutrality by 2030,” said Jeannette Ferran Astorga, Executive Vice President, Corporate Affairs, Communications and Sustainability at Zoetis. “Launching our expanded climate ...
January 4, 2022
Simparica Trio proven to block the pathogen that causes Lyme disease by killing deer ticks PARSIPPANY, N.J. –January 4, 2022– Zoetis today announced that the U.S. Food and Drug Administration (FDA) has approved a new label indication for Simparica Trio ® (sarolaner, moxidectin, and pyrantel chewable tablets) for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks (black-legged or deer ticks).  Simparica Trio is approved for dogs eight weeks of age and older weighing 2.8 pounds and greater. Simparica Trio is the first and only combination product demonstrated to prevent infections that may cause Lyme disease by killing deer or black-legged ticks. “Tick-borne diseases are a serious threat to pets and Lyme disease, caused by Borrelia burgdorferi , is transmitted by deer ticks. It is critical to have easily accessible and effective options for preventing infections available to protect dogs from ticks so ...